Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer

Osumi, Hiroki; Shinozaki, Eiji; Ooki, Akira; Shimozaki, Keitaro; Kamiimabeppu, Daisaku; Nakayama, Izuma; Wakatsuki, Takeru; Ogura, Mariko; Takahari, Daisuke; Chìn, Keisho; Yamaguchi, Kensei

doi:10.1002/cam4.4384

Cited by 11 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possible relationship between ctDNA and selected oncomarkers has already been investigated in smaller studies in tumors other than NSCLC, albeit with conflicting results [28][29][30]. Although, for example, a relationship between CEA and ctDNA was described in colorectal cancer, no relationship to CEA was observed in gastric cancer [29,30]. Similarly, in pancreatic cancer, no relationship between either CEA or CYFRA 21-1 and ctDNA was observed [28].…”

Section: Discussionmentioning

confidence: 99%

Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC

et al. 2023

View full text Add to dashboard Cite

Purpose: To investigate potential association between selected tumor markers and laboratory parameters (lactate dehydrogenase [LDH], neutrophils, hemoglobin, neutrophils, lymphocytes, C-reactive protein, albumin, carcinoembryonic antigen, and cytokeratin 19 fragment 21-1 [CYFRA 21-1]) and circulating tumor DNA (ctDNA) with survival in patients with advanced non-small cell lung cancer (NSCLC). Patients and Methods: The study encompassed 82 patients from a single center. All patients had (localy-) advanced adenocarcinomas. ctDNA was determined before starting therapy and at 6 weeks follow-up. Laboratory parameters were measured before each cycle of therapy and oncomarkers before starting the therapy as standard clinical practice. Mann-Whitney U test, Cox proportional hazards model, Fisher's exact test, and Kaplan-Meier survival estimation with Gehan-Wilcoxon test were used for statistical analysis of the corresponding variables. Results: We have confirmed predictive or prognostic significance for some of the selected laboratory markers and oncomarkers. Above all, we demonstrate a significant relationship between the levels of LDH and the oncomarker CYFRA 21-1 and the presence or absence of ctDNA at the time of diagnosis. We also demonstrate significantly lower CRP levels in patients within whom the ctDNA disappeared during treatment. A similar but statistically insignificant trend was observed for LDH. Conclusions: CYFRA 21-1, LDH and probably CRP correlate with ctDNA levels in NSCLC. Repeated measurement of these markers could thus help in early detection of disease progression in the same way as does ctDNA monitoring.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The overall concordance rate between the ctDNA and CEA levels was 75.5% (83/110). Additionally, the correlation coefficient between ctDNA and CEA levels was lower in patients without liver and lymph node metastases (r = 0.18, p = 0.44) than in patients with liver metastasis (r = 0.48, p < 0.0001) [ 37 ].…”

Section: Overview Of Liquid Biopsies: Ctdnamentioning

confidence: 99%

Circulating Tumor DNA and Management of Colorectal Cancer

Krell,

Llera,

Brown

2023

Cancers

View full text Add to dashboard Cite

Although the incidence of colorectal cancer (CRC) has decreased as a result of increased screening and awareness, it still remains a major cause of cancer-related death. Additionally, early detection of CRC recurrence by conventional means such as CT, endoscopy, and CEA has not translated into an improvement in survival. Liquid biopsies, such as the detection circulating tumor DNA (ctDNA), have been investigated as a biomarker for patients with CRC in terms of prognosis and recurrence, as well as their use to guide therapy. In this manuscript, we provide an overview of ctDNA as well as its utility in providing prognostic information, using it to guide therapy, and monitoring for recurrence in patients with CRC. In addition, we discuss the influence the site of disease may have on the ability to detect ctDNA in patients with metastatic CRC.

show abstract

“…In an analysis of the IDEA- between CEA and ctDNA. 78 Moreover, many tumours do not make CEA at baseline preoperatively. The question is: how do we adjust our adjuvant treatment strategies for positive or negative ctDNA?…”

Section: Minimal Residual Disease In Colorectal Cancermentioning

confidence: 99%

Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers

Mukherji¹,

Alqahtani²,

Winters³

et al. 2022

Oncology &Amp; Haematology

View full text Add to dashboard Cite

Despite our modern perioperative therapies, many patients with gastrointestinal cancer relapse after surgery. Novel strategies to identify and treat patients at high risk of relapse are needed to improve cancer outcomes. Circulating tumour DNA (ctDNA) is a promising, non-invasive biomarker with the potential to identify the earliest signs of cancer relapse. The presence of tumourspecific DNA in the blood in the absence of visualized tumour is suggestive of minimal residual disease and forebodes measurable relapse. Genomic sequencing techniques have advanced over the past few decades, and we have become better able to detect significantly low levels of DNA circulating in the blood from low-volume disease. Numerous studies using various technologies have established ctDNA as a powerful prognostic biomarker for relapse and survival in gastrointestinal cancers. ctDNA has the potential to risk-stratify patients in the postoperative, post-adjuvant and longitudinal settings for therapeutic escalation or de-escalation strategies. It may also capture early tumour dynamics in response to therapeutic intervention. As the multifaceted potential of ctDNA is attracting the attention of researchers, clinicians and patients, many questions remain regarding its use, interpretation and limitations. Here, we discuss the current understanding of ctDNA for minimal residual disease evaluation in gastrointestinal cancers and potential future directions.

show abstract

Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer

Cited by 11 publications

References 29 publications

Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC

Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC

Circulating Tumor DNA and Management of Colorectal Cancer

Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers

Contact Info

Product

Resources

About